MicroStockHub Allakos ( NASDAQ: ALLK ) shares dropped on Wednesday after the biotech posted data from a Phase 1 trial for AK006, its most advanced drug candidate targeted at immune-mediated diseases such as chronic spontaneous urticaria (CSU). Citing data from healthy volunteers, the San Carlos, California-based biotech said that trial subjects tolerated up to 720 mg of AK006 in single and multiple doses, indicating no serious adverse events. There were no treatment-emergent adverse events that forced trial participants to discontinue the therapy, and there were no toxicities, the company added.
Today’s data came from a study testing intravenous and subcutaneous doses of AK006 in healthy participants and CSU patients. The readout represented healthy volunteers who received intravenous AK006 or placebo. Data from CSU patients receiving the IV form of the therapy is expected later this year.
More on Allakos Seeking Alpha’s Quant Rating on Allakos Historical earnings data for Allakos Financial information for Allakos.
